Glirike (Gliclazide)

Glirike (gliclazide) is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

• As monotherapy in patients with newly diagnosed type 2 diabetes.
• As add‑on therapy to metformin or other oral antidiabetic agents.
• In combination with lifestyle modifications to improve fasting and post‑prandial glucose levels.
• For patients who require a sulfonylurea with a lower risk of hypoglycemia compared with older agents.

The safety profile of Glirike reflects the typical effects observed with sulfonylurea agents, ranging from mild, frequently reported events to rare but serious reactions.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed or alcohol is consumed.
• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as skin rash, itching, or swelling.
• Hematologic abnormalities like leukopenia or thrombocytopenia.
• Liver function abnormalities indicated by elevated transaminases.

Before initiating Glirike, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

• Assess renal and hepatic function, as impairment can affect drug clearance.
• Use caution in elderly patients due to higher susceptibility to hypoglycemia.
• Review concomitant use of other hypoglycemic agents to avoid additive glucose‑lowering effects.
• Advise patients to report any signs of allergic reaction or unexplained bruising.
• Pregnancy is classified as category C; the medication should be used only if potential benefits outweigh risks.
• Patients with a history of cardiovascular disease should be monitored closely for cardiac symptoms.

Glirike may interact with other medicines, altering blood glucose levels or increasing the likelihood of side effects; awareness of these interactions supports safe therapy.

Avoid

• Concurrent use with other sulfonylureas or insulin, which can cause profound hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliclazide concentrations.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can affect glucose tolerance.
• NSAIDs or aspirin, which may potentiate hypoglycemic effects.
• Alcohol, especially in excess, which can enhance hypoglycemia risk.